Takada M, Usui N, Yoshida K, Hirayama H, Suzuki M, Takeuchi H, Wada H, Iwasa T, Yamamoto T, Nagasawa I
Department of Obstetrics and Gynecology, Juntendo University School of Medicine, Tokyo.
Nihon Sanka Fujinka Gakkai Zasshi. 1990 Apr;42(4):333-8.
The current study covered 159 patients with primary malignant ovarian carcinoma who underwent various kinds of chemotherapy between 1977 and 1987. The cases in each stage were first divided into two groups. Group A (CDDP Group) and Group B (non-CDDP Group), for comparative analysis. The stage I Group was further divided into Subgroup A (CAP Group) and Subgroup B (FAM Group). Similarly, the Stage III Group was subdivided into Subgroup A (three or more courses of ip administration of CDDP). Subgroup B (three or more courses of iv administration of CDDP centering on CAP), Subgroup C (FAM Group), and Subgroup D (non-CDDP Group). In Stage I, the five-year survival rate in Group A was 94% and the comparable figure in Group B was 59%. In Stage III, the two-year and five-year survival rates were 31% and 11% for Group A as opposed to 24% and 18% for Group B. In Stage Ia, the five-year survival rate for Subgroup A was 90% as compared to 75% for Subgroup B. In Stage III, the two-year survival rate for Subgroup A was 67% as compared to 28% for Subgroup B and 30% for Subgroup C. This indicated a very good prognosis in Subgroup A as compared with the other two subgroups.
本研究涵盖了1977年至1987年间接受各种化疗的159例原发性恶性卵巢癌患者。每个阶段的病例首先分为两组。A组（顺铂组）和B组（非顺铂组），进行对比分析。I期组进一步分为A亚组（CAP组）和B亚组（FAM组）。同样，III期组细分为A亚组（腹腔内给予顺铂三个或更多疗程）、B亚组（以CAP为中心静脉给予顺铂三个或更多疗程）、C亚组（FAM组）和D亚组（非顺铂组）。在I期，A组的五年生存率为94%，B组的相应数字为59%。在III期，A组的两年和五年生存率分别为31%和11%，而B组分别为24%和18%。在Ia期，A亚组的五年生存率为90%，B亚组为75%。在III期，A亚组的两年生存率为67%，B亚组为28%，C亚组为30%。这表明与其他两个亚组相比，A亚组的预后非常好。
